Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL
Dr. Shah and colleagues dissect the social determinants of health, including limited personal resources, frailty, distance to treatment facilities, therapeutic compliance, and other considerations that impact effective treatment sequencing for patients with relapsed or refractory ALL, including access to care and CAR-T cell availability.
EP: 1.Faculty Introductions
EP: 2.Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL
EP: 3.Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL
EP: 4.Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial
EP: 5.Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease
EP: 6.Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion
EP: 7.Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)
EP: 8.Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy
Now Viewing
EP: 9.Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL
EP: 10.Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia
Related Videos
Related Content
